Plan B - Open Access
Master of Science (MS)
Biology and Microbiology
Radiotherapy is commonly used in a variety of tumor types and is effective in control of long term progression and may be curative under certain circumstances. Radiotherapeutics have been shown to be the single most effective therapeutic for cancer and only account for 5% of the total cost. However, treatment of cells with radiation causes the tumor microenvironment to undergo changes and leads to cycles of hypoxia inside the tumor which allows for the cell to undergo angiogenesis, metastasize and may lead to repopulation of the tumor. Current systemic chemotherapeutics typically have an additive toxicity due to the unintended targeting of non-cancerous cells. A nanoparticle conjugated with the iRGD peptide is proposed to allow for selective uptake by the CendR pathway in the tumor tissues. A systemic selective chemotherapeutic agent that will inhibit hypoxia inducible factor- 1, preventing angiogenesis, that is co-administered with radiotherapy may increase the clinical efficacy of the radiotherapeutics and may have the greatest impact on currently available cancer treatment.
Includes bibliographical references
Number of Pages
South Dakota State University
In Copyright - Educational Use Permitted
Walz, Austin Levi, "Increasing the Clinical Efficacy of Radiotherapeutics for Solid Tumors by Inhibition of Hypoxia Inducible Factor-1a" (2018). Biology and Microbiology Graduate Students Plan B Research Projects. 2.